Featuring perspectives from Prof Rebecca A Dent, Dr Hans Lee, Dr Neel Pasricha and Dr Tiffany A Richards, including the following topics: 

• Introduction: The Patient Experience (0:00)
• Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Dr Pasricha (10:28)
• Ocular Toxicities in Multiple Myeloma (45:33)
• Ocular Toxicities in Breast Cancer (50:34)

CME information and select publications

Featuring an interview with Dr Jacob Sands, including the following topics:

• Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00)
  • Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract 
  • Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623.
• Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23)
  • Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593. 
• Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12)
  • Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract
  • Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501.
  • Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521.
• Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11)
  • Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract

CME information and select publications

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: 

• Introduction: ER-Positive Metastatic Breast Cancer — Bringing Research Data into Practice (0:00)
• Key Issues from the General Medical Oncologists (GMO) Survey (3:43)
• Faculty Cases and GMO Questions (44:43)

CME information and select publications

Featuring an interview with Ms Charise Gleason, including the following topics:

• Progress and change in the management of multiple myeloma (MM) (0:00)
• Patient- and disease-specific factors guiding therapeutic decision-making for newly diagnosed MM (5:11)
• Role of anti-CD38 antibodies in the management of MM (12:14)
• Emerging treatment options for smoldering myeloma (23:08)
• Optimizing long-term outcomes for patients with MM (25:38)
• Tailoring therapy for older adults and patients with preexisting comorbidities (29:59)
• Case: A woman in her early 80s with newly diagnosed transplant-ineligible MM who experienced a complete response with first-line daratumumab/lenalidomide and low-dose dexamethasone (34:34)
• Case: A man in his early 60s with progressive back pain from standard-risk MM who experienced a complete response with daratumumab with lenalidomide/bortezomib/dexamethasone (42:05)
• Building therapeutic relationships and integrating holistic care in oncology practice (47:13)

NCPD information and select publications

Featuring an interview with Prof Xavier Leleu including the following topics:

• Introduction: Historical treatment advances in multiple myeloma (MM) (0:00)
• Contemporary treatment for patients with newly diagnosed MM who are eligible for transplant (13:18)
• Prognosis and life expectancy for patients with MM (19:39)
• Mechanistic differences among anti-CD38 monoclonal antibodies (27:05)
• Routes of administration of anti-CD38 monoclonal antibodies (30:21)
• Background and treatment of smoldering myeloma (41:05)
• Treatment for older patients with newly diagnosed MM who are not eligible for transplant (46:41)

NCPD information and select publications

Featuring an interview with Dr Erika Hamilton, including the following topics:

• Monitoring, mitigating and managing adverse events with antibody-drug conjugates (ADCs) for breast cancer (0:00)
  • Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
• Management protocols for adverse events associated with sacituzumab govitecan (7:49)
  • García JMP et al. Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients with triple-negative or HR+/HER2- advanced breast cancer (ABC; PRIMED): A phase 2 trial. ASCO 2024;Abstract 1101.
  • Pérez-García JM et al. Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative advanced breast cancer (PRIMED): An open-label, single-arm, phase 2 trial. eClinicalMedicine 2025;85:103309. Abstract
• Datopotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease (10:51)
  • Tarantino P et al. DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease. ASCO 2025;Abstract TPS1134.
• Sequencing ADCs in breast cancer (13:12)
  • Pacholczak-Madej R et al. Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions. Biochim Biophys Acta Rev Cancer 2025;[Online ahead of print]. Abstract

CME information and select publications

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics: 

• Introduction (0:00)
• A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06)
• Clinical Trials (12:34)
• Chimeric Antigen Receptor Therapy (16:11)
• Bispecific Antibodies (21:38)
• Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45)
• Treatment Options for Relapsed Disease (40:46)
• Neuropathy (44:43)
• Alternative Therapies (48:36)
• 164 Questions (53:20)

CME information and select publications

Featuring perspectives from Dr Haley Ellis and Dr James J Harding, including the following topics: 

• Introduction: Is Biliary Tract Cancer (BTC) the New Non-Small Cell Lung Cancer? … Why? (0:00)
• Case: A woman in her mid 70s with metastatic cholangiocarcinoma receives first-line gemcitabine/cisplatin with durvalumab — Warren S Brenner, MD (8:42)
• Case: A man in his late 70s with metastatic biliary cancer (HER2 IHC 2+) discontinues first-line chemotherapy/immunotherapy because of exacerbation of Crohn’s disease — Neil Morganstein, MD (17:48)
• Case: A man in his early 70s with metastatic cholangiocarcinoma (FGFR2 rearrangement) receives gemcitabine/oxaliplatin with durvalumab and experiences a rapid clinical decline — Kimberly Ku, MD (27:14)
• Case: A woman in her late 40s with Stage IV recurrent cholangiocarcinoma (FGFR2 rearrangement) receives pemigatinib — Justin Peter Favaro, MD, PhD (40:15)
• Case: A woman in her early 60s with HER2-positive cholangiocarcinoma develops metastatic disease during adjuvant capecitabine therapy — Dr Morganstein (46:09)

CME information and select publications

Featuring an interview with Dr Sarah Sammons, including the following topics:

• Development of brain metastases in patients with HER2-positive and HER2-negative breast cancer (0:00)
• Local therapy approaches for the treatment of brain metastases (8:23)
• Treatment options for patients with HER2-positive breast cancer and CNS-only disease progression (16:36)
• Clinical presentation of leptomeningeal disease; management of functional sequelae associated with brain metastases (19:07)
• Investigational agents for the treatment of brain metastases in HER2-positive breast cancer (25:01)
• Case: A 65-year-old woman with ER-negative, HER2-positive metastatic breast cancer (mBC) develops a single 6-mm brain metastasis after 4 years of maintenance trastuzumab/pertuzumab (27:38)
• Screening for brain metastases; radiation necrosis as a side effect of radiation therapy (31:00)
• Case: A 39-year-old woman with ER-negative, HER2-positive mBC develops 7 new brain metastases 6 months into treatment with a taxane, trastuzumab and pertuzumab (34:30)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Sarah Sammons.

CME information and select publications